NCT00929370View on ClinicalTrials.gov

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

March 31, 2009

Conditions
Schizophrenia
Interventions
DRUG

Glycine Transporter-1 inhibitor

GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).

Trial Locations (2)

77401

GSK Investigational Site, Bellaire

91206

GSK Investigational Site, Glendale

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00929370 - A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam. | Biotech Hunter | Biotech Hunter